1458 GMT - Novo Nordisk's trial results for its new CagriSema weight-loss drug failed to impress, Stifel analyst Eric Le Berrigaud writes. This was the second phase 3 trial to evaluate CagriSema, this time in obese patients with diabetes. The type 2 diabetes population has a higher unmet need and CagriSema was expected to show a greater benefit in diabetic patients than in those without the disease. The results therefore remove a clear upside scenario, he says. "CagriSema does not seem to add a lot versus Eli Lilly's Tirzepatide either." Shares fall 3.2%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 11, 2025 10:58 ET (14:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。